Rice, Baylor win defense grant to advance metastasis study

NEWS RELEASE

Jeff Falk
713-348-6775
jfalk@rice.edu

Mike Williams
713-348-6728
mikewilliams@rice.edu

Research promises to improve ability of drugs to target tough-to-treat bone cancers

HOUSTON – (Aug. 19, 2021) – Rice University chemist Han Xiao and biologist Xiang Zhang at Baylor College of Medicine have won a $2.3 million Department of Defense grant to expand their efforts to halt bone cancer metastasis.

Han Xiao

Xiang Zhang

The three-year grant is a Level 2 Breast Cancer Research Program Breakthrough Award, through which the department’s U.S. Army Medical Research and Development Command “challenges the scientific community to design research that will address the urgency of ending breast cancer.”

Xiao and Zhang are targeting bone cancer metastasis by coupling a molecule used to treat osteoporosis, alendronate, with the HER2-targeting antibody trastuzumab used to treat breast cancer. A study released earlier this year showed the antibody conjugate called BonTarg, which relies on Xiao’s pClick technology, significantly enhances the concentration of the antibody at tumor sites.

Experiments showed the treatment could also inhibit secondary metastasis from infected organs seeded by bone tumors. They noted at the time that 20 to 40% of breast cancer survivors eventually suffer metastases to distant organs, with metastasis to bone occurring in about 70% of cases.

Xiao said the previous study applied to tumors related to patients whose breast cancers are related to the overexpression of HER2 protein. The new grant will allow the team to expand their study to a wider patient population.

“The grant will also allow us to improve the therapeutic effect but also to explore the mechanism of our drug,” Xiao said. “Ultimately, we hope this grant will help us push toward a Phase 1 clinical trial.”

Xiao is the Norman Hackerman-Welch Young Investigator, the Cancer Prevention and Research Institute of Texas (CPRIT) Scholar in Cancer Research and an assistant professor of chemistry, bioengineering and biosciences. Zhang is the William T. Butler, M.D., Endowed Chair for Distinguished Faculty, McNair Scholar, associate director of the Lester and Sue Smith Breast Center, professor of molecular and cellular biology and member of the Dan L Duncan Comprehensive Cancer Center.

-30-

Follow Rice News and Media Relations via Twitter @RiceUNews.

Related materials:

Antibodies get easy upgrade with pClick: http://news.rice.edu/2018/11/05/antibodies-get-easy-upgrade-with-pclick-2/

Drug doubles down on bone cancer, metastasis: http://news.rice.edu/2021/06/23/drug-doubles-down-on-bone-cancer-metastasis-2/

Xiao Lab: https://xiao.rice.edu/People/hanxiao/hanxiao.html

Xiang Zhang Lab: https://www.bcm.edu/research/labs-and-centers/faculty-labs/xiang-zhang-lab

Wiess School of Natural Sciences: https://naturalsciences.rice.edu

Image for download:

https://news2.rice.edu/files/2021/05/0517_BONE-34-WEB.jpg

Xiang Zhang, left, at Baylor College of Medicine, and Han Xiao at Rice University have have won a $2.3 million Department of Defense grant to expand their efforts to defeat bone cancer metastasis. (Credit: Rice University/Baylor College of Medicine)

Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 3,978 undergraduates and 3,192 graduate students, Rice’s undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 1 for quality of life by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance.